Research, Reviewed AboutDisclosureContact
PeptideCurator
Research, Reviewed
News

The July 2026 Committee Vote

Seven peptides went to an FDA advisory committee on 23 and 24 July 2026. Six came out with a yes. Not one vote was close to unanimous, and that is the part almost every write-up got wrong.

Data sheet · Updated August 2026 · How we source this
A committee room after a hearing
7
Compounds voted on
6
Recommended
1
Turned down
0
Votes that were unanimous
Every one was narrow

Every vote, widest margin first

Epitalon
7
4
7 yes 4 no
Semax
8
5
8 yes 5 no
BPC-157
8
6
1
8 yes 6 no 1 sat out
KPV
8
6
1
8 yes 6 no 1 sat out
MOTS-c
7
5
2
7 yes 5 no 2 sat out
TB-500
8
6
1
8 yes 6 no 1 sat out
Emideltide (DSIP)
6
7
1
6 yes 7 no 1 sat out

Bars show yes, no, and members who sat out. The widest margin all meeting was three votes. Several came down to two.

How far this actually goes

  1. ✓
    Panel vote
    Done
  2. 2
    FDA decides
    Waiting
  3. 3
    Rule written
    Not started
  4. 4
    Pharmacy may compound
    Not started

The committee advises. It does not decide. One step of four is complete.

What it means, and what it does not

True today
  • A committee recommended six compounds for the 503A list
  • Every one of those votes was narrow
  • The tallies are on the public record
  • The FDA now has advice it did not have before
Not true, however it was reported
  • The FDA approved these peptides
  • Any vote was unanimous or overwhelming
  • A pharmacy can compound them now
  • Anything changed about what is sold online

Three things the coverage skipped

  1. FDA's own scientists argued against several of these.

    The panel voted the other way. That disagreement is on the record and it matters, because the FDA is the body that decides next.

  2. Every vote was narrow.

    Eight to six. Seven to five. Seven to four. Move one or two people in the room and several of these go the other way.

  3. Emideltide and DSIP are the same thing.

    Emideltide is the formal name. DSIP, delta sleep-inducing peptide, is what it is sold as. It was the one the committee refused.

How this got here

  1. 2023
    The door closes

    The FDA sorts a batch of peptides into a category that stops compounding pharmacies from using them. The reasons given are safety questions and thin evidence.

  2. 2023 – 2026
    The market moves, not the compounds

    The pharmacy route shut. The research supply route did not. The same jars kept selling. No pharmacist, no prescription, no one in the middle.

  3. 23 July 2026
    Day one

    BPC-157, KPV and TB-500 each pass 8 to 6 with one member sitting out. MOTS-c passes 7 to 5 with two sitting out.

  4. 24 July 2026
    Day two

    Semax passes 8 to 5. Epitalon passes 7 to 4. Emideltide is refused, 6 to 7, with one sitting out.

  5. Now
    The FDA has not answered

    There is no deadline. There is no draft rule. Nothing has changed for any pharmacy.

A committee said yes, by two votes, over the objection of the agency's own scientists. That is a real result. It is not approval, and it is not a landslide.
Nothing on this page says any compound does anything for anyone. None of them is approved for people to take. Talk to a doctor about your health.